ACCELERON PHARMA INC·4

Sep 26, 4:50 PM ET

ACCELERON PHARMA INC 4

4 · ACCELERON PHARMA INC · Filed Sep 26, 2013

Insider Transaction Report

Form 4
Period: 2013-09-24
Maniatis Tom
Director
Transactions
  • Conversion

    Common Stock

    2013-09-24+25,108250,108 total
  • Conversion

    Common Stock

    2013-09-24+9,261259,369 total
  • Conversion

    Common Stock

    2013-09-24+5,348264,717 total
  • Conversion

    Series A Convertible Preferred Stock

    2013-09-2425,1080 total
    Common Stock (25,108 underlying)
  • Conversion

    Common Stock

    2013-09-24+714265,431 total
  • Conversion

    Series D Convertible Preferred Stock

    2013-09-247140 total
    Common Stock (714 underlying)
  • Conversion

    Series B Convertible Preferred Stock

    2013-09-249,2610 total
    Common Stock (9,261 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2013-09-245,3480 total
    Common Stock (5,348 underlying)
Footnotes (1)
  • [F1]Upon closing of the Issuer's initial public offering, each share of Series A, B, C and D Convertible Preferred Stock automatically converted into one share of Common Stock without payment of further consideration. The shares had no expiration date.

Documents

1 file
  • 4
    edgar.xmlPrimary

    FORM 4 -